Apixaban

A legújabb orális antikoaguláns Magyarországon pitvarfibrillációban szenvedô betegek kezelésére

Translated title of the contribution: Apixaban: The newest oral anticoagulant in hungary for the treatment of patients with atrial fibrillation

Research output: Contribution to journalArticle

Abstract

In the past few years a number of articles have been published on the new oral anticoagulants (Xa-factor inhibitors, thrombin inhibitors). These new agents are increasingly used in the daily clinical practice in Hungary. The new oral anticoagulants have been shown to be at least as effective in the prevention of stroke and systemic embolization related to non-valvular atrial fibrillation as K vitamin antagonists. Moreover, their use is safe, can be administered in a daily fixed dose and, even in case of long-term use, they do not require regular laboratory testing. This review aims to summarise the most important theoretical and practical information on the newest direct Xa-factor inhibitor agent apixaban from the perspective of a cardiologist.

Original languageHungarian
Pages (from-to)181-187
Number of pages7
JournalLege Artis Medicinae
Volume23
Issue number3-4
Publication statusPublished - 2013

Fingerprint

Hungary
Anticoagulants
Atrial Fibrillation
Factor Xa
Vitamin K
Thrombin
Stroke
Therapeutics
apixaban
Cardiologists
Factor Xa Inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{a598c46ad2614f71bd53328129c438e5,
title = "Apixaban: A leg{\'u}jabb or{\'a}lis antikoagul{\'a}ns Magyarorsz{\'a}gon pitvarfibrill{\'a}ci{\'o}ban szenved{\^o} betegek kezel{\'e}s{\'e}re",
abstract = "In the past few years a number of articles have been published on the new oral anticoagulants (Xa-factor inhibitors, thrombin inhibitors). These new agents are increasingly used in the daily clinical practice in Hungary. The new oral anticoagulants have been shown to be at least as effective in the prevention of stroke and systemic embolization related to non-valvular atrial fibrillation as K vitamin antagonists. Moreover, their use is safe, can be administered in a daily fixed dose and, even in case of long-term use, they do not require regular laboratory testing. This review aims to summarise the most important theoretical and practical information on the newest direct Xa-factor inhibitor agent apixaban from the perspective of a cardiologist.",
keywords = "Apixaban, Atrial fibrillation, Prevention, Stroke",
author = "A. Borb{\'e}ly and I. {\'E}des",
year = "2013",
language = "Hungarian",
volume = "23",
pages = "181--187",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "3-4",

}

TY - JOUR

T1 - Apixaban

T2 - A legújabb orális antikoaguláns Magyarországon pitvarfibrillációban szenvedô betegek kezelésére

AU - Borbély, A.

AU - Édes, I.

PY - 2013

Y1 - 2013

N2 - In the past few years a number of articles have been published on the new oral anticoagulants (Xa-factor inhibitors, thrombin inhibitors). These new agents are increasingly used in the daily clinical practice in Hungary. The new oral anticoagulants have been shown to be at least as effective in the prevention of stroke and systemic embolization related to non-valvular atrial fibrillation as K vitamin antagonists. Moreover, their use is safe, can be administered in a daily fixed dose and, even in case of long-term use, they do not require regular laboratory testing. This review aims to summarise the most important theoretical and practical information on the newest direct Xa-factor inhibitor agent apixaban from the perspective of a cardiologist.

AB - In the past few years a number of articles have been published on the new oral anticoagulants (Xa-factor inhibitors, thrombin inhibitors). These new agents are increasingly used in the daily clinical practice in Hungary. The new oral anticoagulants have been shown to be at least as effective in the prevention of stroke and systemic embolization related to non-valvular atrial fibrillation as K vitamin antagonists. Moreover, their use is safe, can be administered in a daily fixed dose and, even in case of long-term use, they do not require regular laboratory testing. This review aims to summarise the most important theoretical and practical information on the newest direct Xa-factor inhibitor agent apixaban from the perspective of a cardiologist.

KW - Apixaban

KW - Atrial fibrillation

KW - Prevention

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84877272046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877272046&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 181

EP - 187

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 3-4

ER -